This volume details protocols ranging from high yield production metabolically labeled KRAS for NMR studies to approaches that quantify engagement of novel molecules that bind KRAS in live cells. Chapters focus on protein production and characterization, biochemical assays, cell-based assays, KRAS-membrane interactions, targeting KRAS, and cell models. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and…mehr
This volume details protocols ranging from high yield production metabolically labeled KRAS for NMR studies to approaches that quantify engagement of novel molecules that bind KRAS in live cells. Chapters focus on protein production and characterization, biochemical assays, cell-based assays, KRAS-membrane interactions, targeting KRAS, and cell models. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.
Authoritative and cutting-edge, KRAS: Methods and Protocols aims to provide methods that will be instrumental in the development of future clinically approved KRAS therapeutics. Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
KRAS as a therapeutic target.- The abundance of KRAS and RAS gene mutations in cancer.- Production of isotopically labeled KRAS4b.- Nucleotide Exchange on RAS Proteins using Hydrolysable and Non-Hydrolysable Nucleotides.- Crystallographic studies of KRAS in Complex with Small Molecules and RAS-binding Proteins.- Considerations around Structure-Based Drug Discovery for KRAS using DOCK.- Measurement of KRAS GTPase activity.- Affinity Measurement of Non-covalent Interactions of the covalent KRAS G12C GDP inhibitor MRTX849 to RAS Isoforms using Surface Plasmon Resonance.- 1D and 2D NMR for KRAS:ligand binding.- Luminescence based techniques for KRAS thermal stability monitoring.- MALDI-TOF mass spectrometry-based assay for measuring covalent target engagement of KRAS G12C inhibitors.- KRAS4b:RAF-1 Homogenous Time-Resolved Fluorescence Resonance Energy Transfer Assay for Drug Discovery.- Biophysical characterization of RAS-SOS Complexes by Native Mass Spectrometry.- Profiling complex RAS-effector interactions using NMR spectroscopy.- Probing RAS Function Using Monobody and NanoBiT Technologies.- Analysis of the guanine nucleotide-bound state of KRAS by ion-pair reversed-phase high-performance liquid chromatography.- Real-time monitoring of RAS activity using in vitro and in-cell NMR spectroscopy.- Studying RAS Interactions in live cells with BRET.- FLIM-FRET Protein-Protein Interaction Assay.- High-throughput cell-based screening of small molecule KRAS signaling inhibitors using a homogeneous time resolved fluorescence (HTRF) assay.- A method to conditionally measure target engagement at intracellular RAS and RAF complexes.- FLAG-KRAS4B as a model system for KRAS4B proteoform and PTM evaluation by mass spectrometry .- Creation of an isogenic H/N/KRAS-less mouse embryonic fibroblast cell line panel derived from a size sorted diploid clone.- Quality Control ofan Isogenic H/N/KRAS-less Mouse Embryonic Fibroblast Cell Line Panel.- A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
KRAS as a therapeutic target.- The abundance of KRAS and RAS gene mutations in cancer.- Production of isotopically labeled KRAS4b.- Nucleotide Exchange on RAS Proteins using Hydrolysable and Non-Hydrolysable Nucleotides.- Crystallographic studies of KRAS in Complex with Small Molecules and RAS-binding Proteins.- Considerations around Structure-Based Drug Discovery for KRAS using DOCK.- Measurement of KRAS GTPase activity.- Affinity Measurement of Non-covalent Interactions of the covalent KRAS G12C GDP inhibitor MRTX849 to RAS Isoforms using Surface Plasmon Resonance.- 1D and 2D NMR for KRAS:ligand binding.- Luminescence based techniques for KRAS thermal stability monitoring.- MALDI-TOF mass spectrometry-based assay for measuring covalent target engagement of KRAS G12C inhibitors.- KRAS4b:RAF-1 Homogenous Time-Resolved Fluorescence Resonance Energy Transfer Assay for Drug Discovery.- Biophysical characterization of RAS-SOS Complexes by Native Mass Spectrometry.- Profiling complex RAS-effector interactions using NMR spectroscopy.- Probing RAS Function Using Monobody and NanoBiT Technologies.- Analysis of the guanine nucleotide-bound state of KRAS by ion-pair reversed-phase high-performance liquid chromatography.- Real-time monitoring of RAS activity using in vitro and in-cell NMR spectroscopy.- Studying RAS Interactions in live cells with BRET.- FLIM-FRET Protein-Protein Interaction Assay.- High-throughput cell-based screening of small molecule KRAS signaling inhibitors using a homogeneous time resolved fluorescence (HTRF) assay.- A method to conditionally measure target engagement at intracellular RAS and RAF complexes.- FLAG-KRAS4B as a model system for KRAS4B proteoform and PTM evaluation by mass spectrometry .- Creation of an isogenic H/N/KRAS-less mouse embryonic fibroblast cell line panel derived from a size sorted diploid clone.- Quality Control ofan Isogenic H/N/KRAS-less Mouse Embryonic Fibroblast Cell Line Panel.- A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826